Hôpital Fondation A. de Rothschild
Paris, 75019, France
Location status: Recruiting
NCT Number: NCT05400590
Keratopathy of patients with aniridia leads to epithelial scarring disorders and a progressive clouding of the cornea linked to this abnormal healing (fibrosis). Treatment with autologous serum is usually undertaken to promote epithelial healing.
However, autologous serum does not prevent the formation of fibrosis, whereas growth factor-rich plasma appears to be associated with a reduction in the in vitro expression of fibrosis markers. This study seeks to compare the in vitro healing and anti-fibrotic properties of autologous serum and growth factor rich plasma from aniridia patients and healthy controls.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Paris, 75019, France
Location status: Recruiting
Blood collection from aniridia patients and healthy controls, half of which will be used to make autologous serum and the other half to make growth factor rich plasma, used for in vitro studies.
A conjunctival impression will also be taken at the inclusion of the patients.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For patients with aniridia:
For controls:
Exclusion criteria
2.5% of body weight
Collection of the most superficial conjunctival epithelial cells (desquamating) in a non- or minimally invasive, quick and almost painless way, for a biological analysis of ocular surface diseases. Application of a filter paper on the bulbar conjunctiva, under local anesthesia.
Time frame: Sampling done at baseline
The corneal cell healing properties are evaluated by the time to reach confluence (number of hours) of epithelial cells, using a standardized wound healing assay (Incucyte, Essenbioscience). The corneal cell healing properties will be comparated between autologous serum, and plasma enriched with growth factors from blood of aniridia patients
Contact information is provided by the study sponsor or research team.
Fondation Ophtalmologique Adolphe de Rothschild
Network
Acronym: CICASAND
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05954403
Aniridia, Anophthalmia
Paris, Île-de-France Region, France
View Trial DetailsNCT06491615
Albinism, Amino Acid Metabolism, Inborn Errors
Bethesda, Maryland, United States
View Trial DetailsNCT01793168
1p36 Deletion Syndrome, 3-Methylglutaconic Aciduria, Type V
Sioux Falls, South Dakota, United States
View Trial DetailsNCT03461978
Acanthamoeba Keratitis, Amebiasis
Vienna, State of Vienna, Austria
View Trial Details